Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Clozapine Induced Cardiomyopathy
Anno:
2025
Clozapine is the most effective medication for treatment of refractory schizophrenia, but it is associated with severe cardiac adverse events including myocarditis and cardiomyopathy. Clozapine-induced cardiomyopathy is more chronic than myocarditis with most cases may be due to undetected myocarditis progressing to dilated cardiomyopathy. Some patients experience a rapid decline…
Leggi di più
Changes in CMR-derived global longitudinal strain, progression of fibrosis and outcome in hypertrophic cardiomyopathy
Anno:
2025
Background: Hypertrophic cardiomyopathy (HCM) is a major health concern, with cardiac magnetic resonance (CMR) playing a crucial role in risk assessment. The utility of sequential CMR, particularly strain analysis, for tracking HCM progression remains to be established. Methods: We evaluated HCM patients undergoing two CMR scans over 10 years….
Leggi di più
Intriguing overlapping of hypertrophic phenotypes
Anno:
2025
Background: Immunoglobulin light chain amyloidosis (LC-A) is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. The major determinant of outcome in LC-A is the extent of cardiac involvement. Both hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) present with…
Leggi di più
UNMASKING THE HIDDEN: A CASE OF ELUSIVE CARDIOMYOPATHY
Anno:
2025
Introduction Hypertrophic cardiomyopathy (HCM) encompasses a spectrum of genetic cardiac disorders characterized by increased thickening of the myocardium. Amyloidosis, a buildup of amyloid, can coexist with or mimic hypertrophic cardiomyopathy, further complicating diagnosis and management. The study of HCM, including its intersection with amyloidosis, is crucial for understanding and…
Leggi di più
A myocarditis on honeymoon
Anno:
2025
Female, 31 years old, in May 2024, while on her honeymoon in Santo Domingo, was stung by an unspecified insect. Upon her return, after about a week, she develops fever unresponsive to home therapy therefore she accesses the infectious emergency room of our AORN, where she is found to…
Leggi di più
AN ATYPICAL PRESENTATION OF ARRHYTHMOGENIC CARDIOMYOPATHY ASSOCIATED WITH DESMOPLAKIN MUTATION
Anno:
2025
A 56-year-old man was referred to our cardiomyopathy clinic by his primary care physician due to persistently low heart rate and suspected left ventricular hypertrophy (LVH) detected on a coronary CT scan performed for nonspecific chest pain. His cardiac history was otherwise unremarkable, except for a family history of…
Leggi di più
Mavacamten, a real game changer in a case of hypertrophic cardiomyopathy with both midventricular and left ventricular outflow tract obstruction
Anno:
2025
A 27-year-old male was diagnosed at the age of 15 with sarcomeric hypertrophic obstructive cardiomyopathy (HOCM) (MYH-7 gene, variant c1816 G>A). No comorbidities. Patient underwent periodic follow-ups showing a predominant mid-ventricular obstruction with evolution in apical aneurysm. He was on beta-blockers. Due to massive septal hypertrophy (30 mm), extensive…
Leggi di più
The embolic dilemma: a rare case of chest pain dued to splenic infarction in a patient with coexisting apical HCM and PFO
Anno:
2025
Introduction Acute left-sided abdominal pain radiated to the left shoulder due to splenic infarction can be confused with cardiogenic thoracic pain. Splenic infarction is frequently linked to infiltrative hematologic disorders, but it can be also related to cardioembolic events. We present the case of a patient admitted to cardiology ward…
Leggi di più
Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis
Anno:
2025
Background: Transthyretin cardiac amyloidosis (ATTR-CA) typically manifests with heart failure (HF). Discontinuing beta-blockers and avoiding angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) in patients with ATTR-CA has been recommended. Methods: We investigated the prescription of neurohormonal therapies and their relationship with all-cause mortality in a multicenter cohort. Results: Patients…
Leggi di più
MAINTENANCE OR IMPROVEMENT OF FUNCTIONAL CAPACITY, HEALTH STATUS, AND QUALITY OF LIFE WITH VUTRISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY: DATA FROM THE HELIOS-B STUDY
Anno:
2025
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) progressively impairs patients’ functional capacity, health status, and quality of life (QOL). In HELIOS-B, vutrisiran reduced all-cause mortality and cardiovascular events compared with placebo in patients with ATTR-CM and demonstrated significant benefit on multiple clinical measures of disease progression. Methods: In HELIOS-B, 6-minute…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram